Browse Newsroom

InsuLife’s Clinical Development R&D Activities Receives Approval From SKATTEFUNN

October 15, 2020

The SkatteFUNN funding scheme from the Research Council of Norway has been approved for our Clinical Development Project spanning R&D activities for the period 2020-2022.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved